Revised Outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported a strong Q3 FY26 (quarter ended 31 Dec 2025). Standalone net sales jumped to Rs 15,992.63 lakhs from Rs 10,184.09 lakhs in Q3 FY25, a growth of about 57% year-on-year. For the nine-month period, revenue rose to Rs 42,291.45 lakhs versus Rs 28,626.86 lakhs last year, up roughly 48%. Profit after tax nearly doubled to Rs 1,047.81 lakhs in Q3 (vs Rs 533.26 lakhs) and stood at Rs 2,697.62 lakhs for 9M FY26, up around 96% YoY. Basic EPS for the quarter was Rs 19.53 versus Rs 11.53 a year ago. The auditor (R.H. Nisar & Co.) issued an unmodified limited review report on both standalone and consolidated results.
Sharp top-line growth of ~57% and PAT growth of ~96% YoY signal strong operating momentum for shareholders, though finance costs have more than doubled which is a watchpoint. Overall, the results are positive and likely to be viewed favorably by the market.